Skip to content

Type 1 diabetes — red flags and safety concerns

TL;DR — The two immediate lethal hazards are insulin deficiency with ketosis/DKA and insulin excess with severe hypoglycemia. Pump interruption can produce ketosis rapidly because no long-acting depot exists; SGLT inhibitors can produce DKA without marked hyperglycemia, so ketone-based assessment matters (Danne 2019, PMID 30728224). Pediatric DKA at diagnosis remains common worldwide (41.9%, 95% CI 39.7–44.0), making polyuria, polydipsia, weight loss, vomiting, dehydration, and altered breathing high-priority recognition signals (Zhang 2026, PMID 42303108). Safety knowledge is a research synthesis, not individualized emergency advice; local emergency protocols govern action.

Emergency pattern recognition

Pattern Signals Immediate concern
New-onset insulin deficiency Polyuria, polydipsia, weight loss, fatigue T1D/stage 3
DKA Vomiting, abdominal pain, dehydration, deep breathing, altered state, ketones Metabolic emergency
Severe hypoglycemia Confusion, seizure, unconsciousness, inability to self-treat External glucose/glucagon and emergency response
Pump delivery failure Rising glucose, repeated ineffective corrections, ketones Rapid insulin deficiency
Euglycemic DKA Symptoms/ketones with modest glucose, especially SGLT exposure Do not exclude DKA from glucose alone
Cerebral injury in DKA Headache, slowing, incontinence, neurologic deterioration Critical pediatric complication

ISPAD provides pediatric DKA/HHS management guidance; fluid, insulin, electrolyte and neurologic monitoring require trained clinical care (Glaser 2022, PMID 36250645).

The PECARN factorial trial randomized 1,389 DKA episodes in 1,255 children to faster/slower rehydration and 0.9%/0.45% saline. Neither infusion rate nor sodium content produced a significant difference in neurologic outcomes, weakening the historical claim that a particular conventional fluid rate is the dominant cause of cerebral injury (Kuppermann 2018, PMID 29897851). It does not make pediatric DKA suitable for unmonitored treatment: neurologic checks, electrolytes, insulin timing, and management of shock remain clinical responsibilities.

DKA at diagnosis

A 233-study meta-analysis covering 380,191 children in 58 countries estimated 41.9% DKA at diagnosis, with country estimates from 15.6% to 78.5% (Zhang 2026, PMID 42303108). This is both disease biology and a health-system indicator.

Prevention layer Target Limitation
Public symptom campaigns Earlier family recognition Effects may decay
Primary-care education Faster testing/referral Low incidence lowers familiarity
Autoantibody screening Presymptomatic identification Infrastructure and cost
Monitoring after positive screen Planned stage-3 diagnosis Retention and psychosocial burden

Sick-day and pump-failure logic

Insulin must not be stopped during illness. Illness can raise insulin requirements even with reduced intake. Vomiting, persistent hyperglycemia, or suspected delivery interruption should prompt glucose plus ketone assessment under the person’s clinical plan.

Check Why
Blood/urine ketones Detect insulin deficiency before severe acidosis
Infusion site/tubing/reservoir Identify delivery failure
Hydration and vomiting Assess dehydration and oral tolerance
Insulin-on-board and corrections Avoid both underdosing and stacking
Backup injected insulin Bypass a failed pump pathway
Escalation threshold Prevent prolonged home management of deterioration

Pump users lack a long-acting subcutaneous depot. Interruption can therefore initiate ketogenesis within hours, and a correction delivered through the same failed set can create false reassurance (Aiello 2025, PMID 37946403). National survey data show material variation among pediatric sick-day protocols despite broad agreement that extra insulin and ketone monitoring are required (Soni 2016, PMID 26903663).

Failure mode Discriminating clue Safety implication
Empty reservoir/occlusion/dislodged cannula Rising glucose despite expected delivery Use a verified backup pathway under the care plan
Spoiled or mishandled insulin Ineffective corrections from more than one site Replace insulin as well as delivery hardware
CGM artifact Meter and symptoms disagree with sensor Confirm with an independent glucose method
Insulin stacking Multiple recent corrections Delayed hypoglycemia after apparent resistance
Gastroenteritis/fasting Vomiting with normal or falling glucose Ketones can still rise; glucose alone is insufficient
Missed basal injection Progressive fasting hyperglycemia/ketosis Restore basal coverage using the prescribed plan

Administrative readiness is part of clinical safety: an unexpired meter and strips, ketone supplies, glucagon, injected rapid-acting insulin, and a written pump-failure dose must exist before a device fails.

SGLT inhibitors and euglycemic DKA

Adjunct SGLT therapy can lower glucose while increasing ketogenesis, producing DKA with glucose below traditional expectations. International consensus recommends risk selection, ketone monitoring, education, and interruption around stressors; it does not eliminate risk (Danne 2019, PMID 30728224).

Higher-risk context Mechanistic concern
Reduced/omitted insulin Loss of anti-ketogenic signal
Low-carbohydrate intake/fasting Increased ketogenesis
Illness/dehydration Counterregulation and impaired clearance
Pump failure Abrupt rapid-acting insulin interruption
Heavy exercise/alcohol Metabolic stress and impaired recognition
Surgery Fasting and stress hormones

The benefit–risk trade-off is quantified rather than theoretical. A 10-trial meta-analysis including 5,961 participants found improved HbA1c and weight outcomes but increased DKA risk with adjunct SGLT inhibition (Lu 2019, PMID 30974510). A separate sotagliflozin meta-analysis reached the same directional conclusion while emphasizing dose and mitigation context (Musso 2019, PMID 30967375). Consensus ketone protocols reduce ambiguity about detection but have not proven that routine risk can be reduced to that of insulin-only therapy.

Glucose-based DKA rules can fail here. Symptoms, acid–base status, and ketones determine the syndrome; a glucose value below a traditional threshold does not rule it out. Reduced insulin to avoid hypoglycemia can paradoxically amplify the anti-ketogenic deficit.

Hypoglycemia safety

Severe hypoglycemia is defined by need for assistance. Impaired awareness and prior events identify higher risk (Rickels 2019, PMID 31389033; Zammitt 2025, PMID 40386839). Ready-to-use glucagon and caregiver training reduce administration complexity (Pieber 2021, PMID 35239971).

Residual C-peptide is associated with less severe hypoglycemia, while low mean glucose, high variability, impaired awareness, sleep, alcohol, renal impairment, exercise, and recent events can compound risk (Gubitosi-Klug 2021, PMID 33529168; Monnier 2020, PMID 31988062). A low alert is not itself a rescue system: sensor lag, alarm audibility, device access, and the ability of another person to administer glucagon all matter.

After seizure, unconsciousness, injury, or external glucagon, the event needs more than a carbohydrate recommendation. Review should cover insulin exposure, preceding activity/alcohol, kidney function, awareness, alarm data, rescue access, and whether driving or safety-critical work should pause under local rules.

Exercise

Exercise response depends on starting glucose, trend, insulin-on-board, intensity, duration, training status, time of day, and prior activity. Aerobic activity often lowers glucose; intense anaerobic work may transiently raise it; delayed nocturnal hypoglycemia can follow either. Consensus emphasizes individualized insulin, carbohydrate, and monitoring strategies (Riddell 2017, PMID 28126459; Adolfsson 2022, PMID 36537529).

CGM exercise guidance adds direction-of-change and timing but retains confirmatory checks when symptoms and sensor values disagree (Moser 2020, PMID 33047169). There is no universally safe pre-exercise glucose because insulin-on-board and activity type change the trajectory. Blanket advice to consume carbohydrate can prevent lows in one context and worsen hyperglycemia or ketosis in another.

Driving and safety-critical work

Hypoglycemia can impair cognition before self-recognition. Safety systems include glucose assessment, trend awareness, rapid carbohydrate availability, response to lows, and review after severe events. Jurisdictional licensing rules vary and should not be inferred from this research page.

Experimental driving-risk work identifies a subgroup with recurrent mishaps and greater neurocognitive vulnerability during hypoglycemia, but small selected samples cannot define licensing policy (Campbell 2010, PMID 21127720). CGM can add trend information, yet compression lows, lag, alarm failure, and phone disconnection mean that device presence is not equivalent to fitness to drive.

Pregnancy and medication cautions

Pregnancy changes insulin needs rapidly and increases consequences of severe dysglycemia; preconception and specialist pathways are required. Drug choices, targets, retinal monitoring, and delivery planning differ from nonpregnant care.

In a 2004–2021 single-center cohort, pregnancy DKA was often associated with vomiting, infection, device problems, or insulin omission and carried serious fetal risk (Dhanasekaran 2022, PMID 35917830). Pregnancy can produce DKA at lower glucose concentrations; nausea should not be assumed benign when ketones or insulin deficiency are plausible. Closed-loop trials show improved pregnancy-specific time in range, but neither automation nor improved mean glucose abolishes acute-event planning (Lee 2023, PMID 37796241; Donovan 2025, PMID 41134589).

Intentional or accidental insulin interruption is never equivalent to stopping an optional drug. Recurrent DKA, unexplained glycemic volatility, or repeated severe hypoglycemia should trigger assessment of supply, devices, cognition, mental health, eating behavior, safeguarding, and regimen fit.

Recurrent acute events are prognostic signals

Recurrent DKA clusters in a minority rather than distributing evenly. A UK cohort of 298 people and 628 admissions found high post-discharge mortality and concentration of risk among recurrent presenters (Gibb 2016, PMID 27397023). A Brazilian cohort likewise found progressively worse survival with repeated admissions (Santos 2023, PMID 37106409). These data support intensive multidisciplinary follow-up but do not justify labeling the cause as behavioral without assessing access and clinical failure modes.

Domain to review after recurrence Examples
Treatment access Rationing, expired prescriptions, coverage gaps, unstable housing
Delivery Infusion failures, lipohypertrophy, damaged insulin, missing backup
Knowledge/communication Sick-day plan, numeracy, language, health literacy
Mental health Distress, depression, suicidality, trauma, eating pathology
Cognition/development Executive function, neurodivergence, transition readiness
Social safety Abuse, neglect, school/work obstruction, caregiver capacity
Classification Autoimmune T1D, ketosis-prone diabetes, monogenic or secondary diabetes

Red flags for classification error

  • Adult labeled type 2 with rapid insulin dependence, ketosis, low/declining C-peptide, or islet autoantibodies.
  • Child labeled T1D with syndromic features, strong multigenerational non-insulin phenotype, or persistently robust secretion.
  • Recurrent hypoglycemia on very low insulin requirements suggesting adrenal, renal, celiac, dosing, or intake problems.
  • Apparent “brittle diabetes” without review of access, infusion sites, insulin handling, data, and psychosocial drivers.

Adult-onset autoimmune diabetes is commonly misclassified; no single age or phenotype is decisive (Evans-Molina 2025, PMID 40230204).

Random C-peptide review can uncover classification errors in long-standing clinician-labeled T1D, but thresholds depend on glucose, renal function, disease duration, and assay (Thewjitcharoen 2023, PMID 36923852). Classification correction must never create an insulin gap while severe deficiency remains possible.

Safety controversies

Controversy Evidence supporting caution Evidence limiting overstatement
DKA fluids cause cerebral injury Cerebral injury occurs during DKA treatment Factorial RCT found no neurologic difference across studied conventional rates/tonicity
Pumps inherently prevent DKA Better glucose management may reduce some events Short-acting-only delivery makes interruption rapidly dangerous
SGLT mitigation makes use safe Ketone education and selection are mechanistically sound Meta-analyses retain excess DKA risk
CGM prevents severe lows Alerts and trend data can enable earlier action Lag, alarm failure, impaired response, and access persist
Recurrent DKA is “noncompliance” Insulin omission can contribute Access, device, psychiatric, cognitive, and classification causes are competing explanations

Open questions

  • Which combination of screening and awareness produces the largest DKA reduction per resource? (Zhang 2026, PMID 42303108)
  • Can pump-failure algorithms detect insulin interruption before clinically meaningful ketosis?
  • Which SGLT-risk mitigation components actually prevent DKA in routine use? (Danne 2019, PMID 30728224)
  • How should driving policy incorporate CGM without penalizing people for data visibility?
  • Which multidisciplinary intervention prevents recurrent DKA most effectively?

References

  1. Riddell MC, et al. Exercise management in type 1 diabetes. Lancet Diabetes Endocrinol. 2017;5:377-390. PMID 28126459
  2. Danne T, et al. Consensus on DKA Risk Management With SGLT Inhibitors. Diabetes Care. 2019;42:1147-1154. PMID 30728224
  3. Rickels MR. Hypoglycemia-associated autonomic failure. Ann N Y Acad Sci. 2019;1454:68-79. PMID 31389033
  4. Pieber TR, et al. Dasiglucagon for severe hypoglycemia. Diabetes Care. 2021;44:1361-1367. PMID 35239971
  5. Glaser N, et al. ISPAD 2022: DKA and HHS. Pediatr Diabetes. 2022;23:835-856. PMID 36250645
  6. Adolfsson P, et al. ISPAD 2022: Exercise. Pediatr Diabetes. 2022;23:1341-1372. PMID 36537529
  7. Evans-Molina C, et al. T1D presenting in adults. Diabetes Obes Metab. 2025. PMID 40230204
  8. Zammitt NN, et al. Predictors of impaired awareness and severe hypoglycaemia. Diabet Med. 2025. PMID 40386839
  9. Zhang T, et al. Worldwide prevalence of DKA at diagnosis of T1D. Prev Med. 2026;210:108625. PMID 42303108
  10. Kuppermann N, et al. Clinical trial of fluid infusion rates for pediatric DKA. N Engl J Med. 2018;378:2275-2287. PMID 29897851
  11. Lu J, et al. SGLT inhibitors added to insulin in T1D: meta-analysis of RCTs. Diabetes Metab Res Rev. 2019;35:e3169. PMID 30974510
  12. Musso G, et al. Sotagliflozin in T1D: meta-analysis of randomized trials. BMJ. 2019;365:l1328. PMID 30967375
  13. Moser O, et al. CGM-based glucose management for exercise in T1D. Diabetologia. 2020;63:2501-2520. PMID 33047169
  14. Monnier L, et al. Glycemic variability and mean glucose as predictors of hypoglycemia. Diabetes Care. 2020;43:821-827. PMID 31988062
  15. Aiello EM, et al. Ketone-based alert system for insulin-pump failures. J Diabetes Sci Technol. 2025;19:683-691. PMID 37946403
  16. Soni A, et al. Management of children with T1D during illness: national survey. Postgrad Med J. 2016;92:447-449. PMID 26903663
  17. Campbell LK, et al. Neurocognition and recurrent driving mishaps in T1D. Int J Diabetes Mellit. 2010;2:73-77. PMID 21127720
  18. Dhanasekaran M, et al. DKA in pregnancy: risk factors, presentation, and outcomes. J Clin Endocrinol Metab. 2022;107:3137-3143. PMID 35917830
  19. Lee TTM, et al. Automated insulin delivery in pregnancy complicated by T1D. N Engl J Med. 2023;389:1566-1578. PMID 37796241
  20. Donovan LE, et al. Closed-loop insulin delivery in T1D pregnancy: CIRCUIT trial. JAMA. 2025;334:2176-2185. PMID 41134589
  21. Gibb FW, et al. Risk of death following hospital admission with DKA. Diabetologia. 2016;59:2082-2087. PMID 27397023
  22. Santos SS, et al. Death after recurrent DKA admissions in young adults with T1D. Diabetol Metab Syndr. 2023;15:85. PMID 37106409
  23. Thewjitcharoen Y, et al. Misdiagnosed adult-onset T1D identified by C-peptide testing. Heliyon. 2023;9:e14262. PMID 36923852
  24. Gubitosi-Klug RA, et al. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest. 2021;131:e143011. PMID 33529168
  25. Peters AL, et al. DKA with canagliflozin in patients with T1D. Diabetes Care. 2016;39:532-538. PMID 26989182